Boston Scientific Announces European Approval of Platinum Chromium TAXUS(R) Element(TM) Stent System

Approval Includes Specific Indication for Treatment of Diabetic Patients

NATICK, Massachusetts, May 12, 2010 - Boston Scientific Corporation (NYSE: BSX) today announced it
has received CE Mark approval for its TAXUS(R) Element(TM) Paclitaxel-Eluting
Coronary Stent System, the Company's third-generation drug-eluting stent
(DES) technology. This approval includes a specific indication for the
treatment of diabetic patients. The TAXUS Element Stent System incorporates a
platinum chromium alloy with an innovative stent design and an advanced
catheter delivery system. The Company plans to launch the TAXUS Element Stent
System next month in the European Union and other CE Mark countries.

"In my experience, the platinum chromium alloy and new stent
design used in the TAXUS Element Stent offer increased flexibility,
visibility and deliverability," said Dean Kereiakas, M.D., Medical Director
at The Christ Hospital Heart and Vascular Center and The Lindner Research
Center in Cincinnati and the Principal Investigator for the PERSEUS clinical
program. "The Element platform represents a significant advance in coronary
stenting with performance improvements that could simplify procedures and
allow treatment of a broader range of patients. The combination of the proven
TAXUS drug and polymer with the new Element platform provides a welcome
treatment option."

"As the worldwide prevalence of diabetes continues to increase
dramatically, the diabetic indication for the TAXUS Element Stent System
represents an important benefit for diabetic patients being treated for
coronary artery disease," said Hank Kucheman, Executive Vice President and
Group President, Cardiology, Rhythm and Vascular for Boston Scientific. "The
TAXUS Element Stent System, with the proven performance of paclitaxel,
provides an advanced treatment option for diabetic patients. This product's
unique mechanism of action helps to inhibit restenosis in high-risk patients
with diabetes, and we are pleased to offer it to these patients."

The TAXUS Element Stent is designed specifically for coronary
stenting and leverages the performance advantages of the Element platform
with a decade of clinical success from the TAXUS program. The novel stent
architecture and proprietary platinum chromium alloy combine to offer greater
radial strength and flexibility. The stent architecture helps create
consistent lesion coverage and drug distribution while improving
deliverability, which is enhanced by an advanced catheter delivery system.
The higher density alloy provides superior visibility and reduced recoil
while permitting thinner struts compared to prior-generation stents[1].

The Company received CE Mark approval for the PROMUS(R)
Element(TM) Everolimus-Eluting Stent System in October 2009. Both Element
systems incorporate the same platinum chromium alloy, innovative stent design
and advanced catheter delivery system.

In March, the Company announced 12-month results from its
PERSEUS clinical program demonstrating positive safety and efficacy outcomes
in workhorse lesions for the TAXUS Element Stent System compared to the
TAXUS(R) Express2(TM) Stent System. The results also reported a similar
safety profile and statistically superior efficacy outcomes in small vessels
for the TAXUS Element Stent compared to a historical control group of
patients receiving the Express(R) bare-metal stent.

"The PERSEUS data confirmed that the proven TAXUS drug and
polymer combination has been successfully transferred to the Element platform
with notable advantages in acute performance," added Kucheman.

The PERSEUS clinical program compared the TAXUS Element Stent
to prior-generation Boston Scientific stents in more than 1,600 patients in
two parallel trials at 90 centers worldwide.

In the U.S., the Company expects Food and Drug Administration
approval for the TAXUS Element Stent System in mid 2011 and for the PROMUS
Element Stent System in mid 2012. In Japan, the Company expects approval for
the TAXUS Element Stent System in late 2011 or early 2012 and for the PROMUS
Element Stent System in mid 2012.

In the U.S., the TAXUS Element Stent and the PROMUS Element
Stent are investigational devices and are limited by applicable law to
investigational use only and are not available for sale.

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like "anticipate,"
"expect," "project," "believe," "plan," "estimate," "intend" and similar
words. These forward-looking statements are based on our beliefs, assumptions
and estimates using information available to us at the time and are not
intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements regarding
clinical trials, regulatory approvals, competitive offerings, product
performance and our market position. If our underlying assumptions turn out
to be incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections expressed
or implied by our forward-looking statements. These factors, in some cases,
have affected and in the future (together with other factors) could affect
our ability to implement our business strategy and may cause actual results
to differ materially from those contemplated by the statements expressed in
this press release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual
property; litigation; financial market conditions; and, future business
decisions made by us and our competitors. All of these factors are difficult
or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A -
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A -
Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

[1] Based on bench testing. Data on file with Boston Scientific.

CONTACT:

    Geraldine Varoqui
    +49(2102)-489-461 (office)
    +49(170)-782-85-58 (mobile)
    International Public Relations
    Boston Scientific Corporation

Geraldine Varoqui, +49(2102)-489-461 (office), +49(170)-782-85-58 (mobile), International Public Relations, Boston Scientific Corporation